Decreasing the Overuse of Troponin Testing- An Interventional Study in a Regional Hospital.


Journal

The American journal of medicine
ISSN: 1555-7162
Titre abrégé: Am J Med
Pays: United States
ID NLM: 0267200

Informations de publication

Date de publication:
12 2020
Historique:
received: 18 06 2020
revised: 19 06 2020
accepted: 19 06 2020
pubmed: 19 7 2020
medline: 7 1 2021
entrez: 19 7 2020
Statut: ppublish

Résumé

The purpose of this study was to determine the effect of recommendations to limit troponin testing to patients with either chest pain or ischemic electrocardiographic changes. We included all adult patients hospitalized in a regional hospital in internal medicine, cardiology, and intensive care departments in 2014-2016 and in 2019 after recommending limiting troponin testing to patients with either chest pain or ischemic electrocardiographic changes. After the intervention, testing decreased from 51.5% (11,634/22,581) to 34.6% (3417/9882). However, if only those with ischemia or chest pain were tested, the frequency would be 9.4% (924/9882) with a 95% confidence interval of 8.8%-9.9%. Variables increasing the odds of ordering a troponin test were older age, male sex, a discharge diagnosis of tachyarrhythmia, congestive heart failure, and dizziness or syncope as well as lower albumin and higher glucose, uric acid, and blood urea nitrogen test results. There were lower odds in those with nonspecific symptoms and infections of the skin, soft tissues, and the urinary tract. Auditing increased the effectiveness of the intervention in 1 internal medicine department (odds ratio 0.70, 95% confidence limit 0.60-0.82) after adjustment for other significant independent variables. The area under the curve was 0.713. We found that an educational program with clear recommendations decreased the proportion of patients with troponin testing in hospitalized internal medicine departments, but the intervention was only partially effective and did not include patients with congestive heart failure and other conditions in which expert recommendations for testing are discordant.

Identifiants

pubmed: 32681829
pii: S0002-9343(20)30595-7
doi: 10.1016/j.amjmed.2020.06.013
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1433-1436

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Zvi Shimoni (Z)

Department of Internal Medicine B, Laniado Hospital, Netanya, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.

Paul Froom (P)

Clinical Utility Department, Sanz Medical Center, Laniado Hospital, Netanya, Israel; School of Public Health, University of Tel Aviv, Israel. Electronic address: froomp@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH